Proud to be part of it! #Fightantimicrobialresistance BIOASTER INCATE #antibiotics INCATE marks its third anniversary of successfully supporting innovators fighting antimicrobial resistance https://lnkd.in/eEpXjP9F About INCATE INCATE is a not-for-profit partnership which brings together translational and basic research, industry, experienced entrepreneurs, and investors from across Europe and beyond. The German Center for Infection Research (DZIF), the Leibniz:HKI (part of Leibniz Association) in Germany, the Swiss National Centre of Competence in Research AntiResist, the University of Basel, are the academic founding members of INCATE, with the University of Basel acting as the host. Together with the four industry partners Boehringer Ingelheim, MSD, Roche, and Shionogi, the Technology transfer organization BIOASTER in France, and US-based venture capital firm Kineticos AMR Accelerator Fund, as well as other organizations, funders and investors, INCATE aims to ensure that the pipeline of new antibiotics and technology platforms is filled and strengthened.
BIOASTER’s Post
More Relevant Posts
-
We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #13. We are talented: We were founded by bright minds. We have attracted highly talented employees and we support them to expand their skills and achievements. Our chairman is world-renowned in the field of rare diseases. Our leadership team is highly experienced and highly regarded. We value camaraderie and interdependencies between us as a team, and with the environment in which we operate. Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery
-
-
Providing the best Talent and Services for your team globally within the Life Science / Biotech sector
🔥 New Biotech Launch Alert! 🔥 A cutting-edge biotech company focused on inflammatory diseases has launched with an impressive $168M in funding! 🎉🧬 Leading this innovative venture is a former Kite leader, bringing a wealth of expertise and experience to the table. 🌟 Key investors in this venture include Atlas Venture, Omega Funds, and F-Prime Capital, whose support underscores the significant potential of this new company. 💡💰 With this substantial investment, the company is poised to develop groundbreaking treatments for inflammatory conditions, aiming to make a significant impact on patient care and outcomes. 🩺 #Biotech #InflammatoryDisease #HealthcareInnovation #FundingNews #BiotechLaunch #MedicalAdvancements #InnovationInHealthcare #ScientificResearch #Biopharma #NewBeginnings #AtlasVenture #OmegaFunds #FPrimeCapital
-
The Aging Research & Drug Discovery Meeting carefully crafted by Daniela Bakula and Morten Scheibye-Knudsen duo at Københavns Universitet - University of Copenhagen will be taken to the next level this year. In addition to top academics, it brings together pharma, investors, biotech companies, and government. Prepare for the best ARDD experience ever! It takes 54-60 weeks to put the conference together, and the preparation starts over a year before the actual conference. Thanks to the move from Basel and Copenhagen's intellectual independence, it remained open even during 2020-2022 with limited on-site participation. Many companies that presented in 2023 successfully raised funding in 2023-2024. We hope to see this trend continue in 2024. #longevity #agingresearch #aging #drugdiscovery #sustainability
-
-
Such a strong group of co-investors in TIAP portfolio company AmacaThera — a clinical-stage #biotech company developing a novel #drugdelivery platform to improve patient outcomes across multiple therapeutic areas — co-founded by the University of Toronto's Drs. Molly Shoichet and Mike Cooke. Find out more about AmacaThera and TIAP's diverse portfolio of 70+ companies at: https://tiap.ca/portfolio/ #OIS2024 #OBIOInvestmentSummit #OBIOInvestmentSummit2024
-
-
BCBN Feed: The Importance of MassBio’s Funding Catalyst in Vision 2030 https://lnkd.in/gsJ2Vp6N At MassBio, we are dedicated to advancing Massachusetts as a global leader in the life sciences sector. As part of our Vision 2030 strategic plan, the goal of the Funding Catalyst is to diversify and enrich the funding landscape for biotech innovators. The initiatives under this catalyst are not just... ... [...]
-
Executive Search Specialist and Portfolio Builder for VCs – MSc in Cell and Molecular Biology
🔍 This week, we unveiled our latest white paper: "Beyond Antibiotics: The Reckoning of Antimicrobial Resistance, A New Biological Frontier". Dive into it to discover more about "Equity investment opportunities in the antimicrobial space: Key considerations for venture capital firms" as we hear insights from Martin Heidecker, Chief Investment Officer at AMR Action Fund. 💼 Investing equity in a challenging market environment: The antibiotic market is broken, with private investment remaining low and stagnant. However, promising equity investment opportunities exist in small and mid-size biotech companies, particularly as they enter the clinic. 🎯 Novel targets and strong data: Developing therapies with novel targets is crucial, offering a unique chance to develop truly next-generation antimicrobials. Companies must meet safety and selectivity criteria while also demonstrating a favourable resistance profile and patient benefit. 👥 Patient benefit and unmet need: The investment focus should be on treating infections caused by high-priority pathogens, representing areas of high unmet medical need. 📈 Clinical development plan and positioning: Companies should explore orphan drug designation and establish long-term incentive plans to keep management motivated. 💡 A strong management team: Management teams play a crucial role in navigating the challenging market environment and securing regional deals. #AMR #Biotech #AntimicrobialResistance #PrivateEquity #VentureCapital
The Reckoning of Antimicrobial Resistance, A new biological frontier
insights.cavenaghhealth.com
-
Today is your last chance to save with Advanced Registration rates for the 24th Bio€quity Europe. Join BioCentury Inc. and EBD Group in San Sebastián, Spain, Basque Country, for this destination event designed for biopharma decision-makers and investors. ➤ Debate how to 'rise above the noise' and reach the discussion stage with investors and pharma. ➤ Network and partner with VCs, CEOs, and BD&L leaders. ➤ Discover 100+ emerging biotechs selected for the Presenting, Next Wave, and Pre-Seed Company Tracks. ➤ Dive into European biotech trends with an exclusive conference report from Insights Partner McKinsey & Company. Register by midnight PST to save with Advanced Registration: https://ow.ly/aSB850R6KU3 Download the conference brochure to learn who you will meet and the agenda: https://ow.ly/1KEi50R6KU2 Special thanks to our Regional Host Committee Diputación Foral de Guipuzcoa and Ysios Capital, and to our Founding Sponsor Sofinnova Partners. #bioequityeurope #biopharma #biotech #lifesciences #bioeurope #bioeuropespring #VCs
-
-
🚀Breaking news!📣 Genomadix proudly unveils one of the first #CubeX Open Platform Partnerships with LuminUltra Technologies Ltd.! Under this partnership, LuminUltra will be developing and commercializing molecular assays for the water, energy and food and beverage industries using the Genomadix Cube qPCR technology using the CubeX Open Platform while also tacking over the #legionella testing business of Genomadix Inc. Steve Edgett, CEO of Genomadix, stated “Genomadix is focused on the development and commercialization of precision medicine tests on the Cube and licensing our CubeX Open Platform to strategic partners. LuminUltra was the perfect home for the legionella business that we had nurtured under the Spartan Bioscience brand. We intend to support a seamless transition with our customers and are thrilled that LuminUltra will bring scale, expertise, and focus to the Legionella business. This agreement is our first CubeX Open Platform strategic partnership. We look forward to more partnerships in other markets in the future.” 🔗 Learn more about the exciting partnership here: https://lnkd.in/egsfVteN #GenomadixCube #LuminUltra #partnership #partnershipannouncement #startups #qpcr #biotechnology #moleculardiagnostics #diagnostics #genotyping #genetictesting #healthcare #precisionmedicine #precisionhealth #microbialmonitoring #publichealth #Pharmacogenetics #Pharmacogenomics #PGx #PGxmovement
-
-
We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #3. We are ambitious: We are driven by our shared mission to discover, develop and deliver impactful medicines to patients using cutting edge science. We are motivated to push boundaries and think big as we tackle challenges we confront as a company. We take a proactive approach towards research, and we are intentional in setting our short-term and long-term goals. Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery
-
-
We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #6. We are focused: To ensure alignment with our mission, we take a focused approach to our delivery. We wisely utilise our resources and pay attention to our priorities. We balance pursuing our ambitious goals and innovations with our ability to ”focus and finish”. We focus on our most important work, and we are clear on our daily priorities to deliver our collective goals and mission. Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery
-
We are proud to have a partner like BIOASTER in supporting early-stage innovators in the fight against antimicrobial resistance. Thank you for you support and for believing in our work.